MedTrace Logo

Hyperpolarized 129Xe MRI Lung Health Cohort

NCT05766384 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2026-05-01

No results posted yet for this study

Summary

A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.

Conditions

  • Healthy

Interventions

DRUG

Hyperpolarized Xe129

Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.

Sponsors & Collaborators

  • Johns Hopkins University

    collaborator OTHER

  • University of Iowa

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • University of Illinois at Chicago

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • Temple University

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • University of Kansas Medical Center

    lead OTHER

Eligibility

Min Age
25 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-30
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05766384 on ClinicalTrials.gov